Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory ...

Replimune stock doubled to $9.00 after FDA accepted its resubmitted application for melanoma drug RP1, with decision expected April 2026.

Replit CEO Amjad Masad says "functional AI" can already automate much of the economy — we don't need true AGI to see major ...

This guide is here to break it all down, giving you the google it automation with python answers you need. We’ll cover the basics, get into the nitty-gritty of Python itself, and show you how to ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...